|Carrolee Barlow, MD, PhD to Lead the Parkinsonís Institute and Clinical Center as Chief Executive Officer|
|Historic Moment as Dr. Barlow becomes the Second CEO since the Instituteís Founding 25 Years Ago |
Founder and Former CEO J. William Langston, MD will continue as Chief Scientific Officer
|Published Wednesday, March 5, 2014|
For Immediate Release
Sunnyvale, CA —The Parkinson’s Institute and Clinical Center announced today that Carrolee Barlow, MD, PhD — renowned expert in neuroscience and neurodegeneration — has become the Institute’s next Chief Executive Officer. Dr. Barlow is the second Chief Executive Officer in the Institute’s 25 year history. She takes the reins from Dr. J. William Langston, who founded the organization in 1988 and has led it ever since.
Dr. Barlow’s previous work has spanned clinical care, laboratory and clinical research, academia, and industry. According to Dr. Langston, “We are exceptionally fortunate to have attracted and recruited Dr. Barlow, and her credentials are beyond impressive. With both a PhD and MD, and extensive research, drug development, and clinical trials experience, I can’t imagine a better fit for this position and the Parkinson’s Institute.”
Dr. Barlow is the former Chief Scientific Officer and Chief Medical Officer of BrainCells, Inc. in San Diego, California, a biotechnology company focused on the discovery and development of small molecules that stimulate adult hippocampal neurogenesis for the treatment of neurological and psychiatric disease using human neural stem cell technology. Prior to BrainCells, she served as the Director of Molecular Neuroscience and Therapeutic Area Head for Stroke and Neurodegeneration at Merck Research Laboratories where she was responsible for neuroscience biology, global exploratory, licensing, and full-phase efforts. Dr. Barlow has held a faculty position in the Laboratory of Genetics at the Salk Institute for Biological Studies in La Jolla, California. She also serves as an advisory board member for several biotechnology companies and disease foundations advancing therapies for rare diseases and disorders of the central nervous system (CNS).
“Two and a half decades ago, Dr. Langston and fellow Parkinson’s disease experts set out to create a better way to research the disease and care for people living with Parkinson’s. Today, I am proud to have joined an organization with such a rich history and demonstrated impact on Parkinson’s disease care and treatment” shared Dr. Barlow. “As we look to the future, it is a very exciting time given the development of new and better treatments for Parkinson’s, and the critical role that the Institute will continue to play.” She continued, “We provide people living with Parkinson’s care of the highest caliber, we are on the forefront of stem cell research, and we are a leader in LRRK2 research and genetic discovery. Our integration of clinical care, laboratory research, clinical research, and clinical trials is powerful. We are uniquely positioned to align the Institute, people living with Parkinson’s and their loved ones, and key stakeholders, including industry and regulatory agencies, in order to innovate and to accelerate the pace at which we expand our understanding of Parkinson’s and bring promising and safe new therapies to people touched by this disease.”
Dr. Barlow received her MD from the University of Utah, did her residency in Internal Medicine at The New York Hospital, Cornell Medical Center, and went on to obtain a PhD in molecular and developmental biology at the Karolinska Medical Nobel Institute in Stockholm, Sweden. Shortly thereafter, she joined the National Institutes of Health and completed medical sub-specialty training in the field of endocrinology and a postdoctoral fellowship in neurogenetics at the National Human Genome Research Institute.
“Dr. Barlow’s energy and expertise will be key to moving the Parkinson’s Institute into the future,” said Dr. Langston, “and I am confident that we can look forward to an exciting and productive future with her leading the way. Indeed, I am really looking forward to it.”
About the Parkinson's Institute and Clinical Center
Two and a half decades ago, a dedicated group of Parkinson’s disease experts set out to create a better way to research and provide care for Parkinson’s disease. Patients would become partners in developing their care plans, improving their quality of life, and discovering new strategies to confront and manage their disease. Compassionate care would work hand in hand with cutting-edge research to seek answers, develop new therapies and treatments, and ultimately work toward a cure. The result was the Parkinson’s Institute and Clinical Center — America’s only independent non-profit organization combining world-class care, clinical research, laboratory research, and clinical trials for Parkinson’s disease under one roof.
Press and Media Inquiries:
Chelsea E.M. Kasai